oxydiaminobenzene

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶二唑类
• 英文名称: oxydiaminobenzene
• 英文别名: 1,3-Dihydro-2,1,3-benzoxadiazole
• 化学式: C₆H₆N₂O
• 分子量: 122.126
• InChiKey: JJDNBBLXPYVGPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  33.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  oxydiaminobenzene 、 三乙胺 、 二氯氟甲基次磺酰氯 生成 、 三乙胺盐酸盐
  参考文献：
  名称：

  BE621711

  摘要：

  公开号：

文献信息

• Substituted Pyrazoles as Ghrelin Receptor Antagonists
  申请人：Ge Min

  公开号：US20090253673A1

  公开（公告）日：2009-10-08

  Certain novel N-acylated spiropiperidine derivatives are ligands of the human ghrelin receptor(s) and, in particular, are antagonists/inverse agonists of the human ghrelin receptor. They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of the ghrelin receptor, such as obesity, diabetes, and metabolic syndrome.

  某些新型N-酰化螺环哌啶衍生物是人类胃饥素受体的配体，特别是人类胃饥素受体的拮抗剂/逆向激动剂。因此，它们对于治疗、控制或预防对胃饥素受体调节敏感的疾病和疾病是有用的，如肥胖症、糖尿病和代谢综合征。
• HETEROCYCLIC COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF
  申请人：SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

  公开号：US20170158680A1

  公开（公告）日：2017-06-08

  The present invention provides a heterocyclic compound represented by the formula (I), its stereoisomers, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and their use in preparing a medicament for the prevention and/or treatment of central nervous system disease.

  本发明提供了一种由公式（I）表示的杂环化合物，其立体异构体，或其药用可接受的盐，其药物组合物，以及它们用于制备预防或治疗中枢神经系统疾病的药物。
• New Herbicides
  申请人：RHONE POULENC AGRICULTURE LTD.

  公开号：EP0508800A1

  公开（公告）日：1992-10-14

  Benzimidazolyl derivatives of formula wherein Y represents:-    an optionally substituted alkyl, alkenyl or alkynyl group; or an optionally substituted cycloalkyl group; or a group -SR, -OR, halogen, aryl or aralkyl; or 2 groups Y form a fused phenyl ring;    R2 represents a group -OH, -NR7R8 or -XM;    A represents a group -SO2NR7R8;    Y1 represents an optionally substituted alkyl, alkenyl or alkynyl group; or an optionally substituted cycloalkyl group; or a group such as -SR, -OR, halogen, aryl, aralkyl, -O-aryl or -NR7R8;    n represents one or two;    m represents an integer from 1 to 4;    R represents an optionally substituted alkyl group; or an optionally substituted cycloalkyl group;    R7 and R8 represent independently a group such as hydrogen, R, aryl or aralkyl; X represents oxygen or sulphur;    M represents an optionally substituted alkyl group; or an optionally substituted cycloalkyl group; or an aryl, aralkyl, alkenyl, alkynyl, or an imine group; agriculturally acceptable salts thereof;    the herbicidal compositions comprising these compounds and their application to crop protection is described.

  Benzimidazolyl衍生物的化学式中，其中Y代表：一个可选择取代的烷基，烯基或炔基团; 或一个可选择取代的环烷基团; 或一个-SR，-OR，卤素，芳基或芳基烷基; 或2个Y形成一个融合苯环; R2代表一个羟基，-NR7R8或-XM的基团; A代表一个-SO2NR7R8的基团; Y1代表一个可选择取代的烷基，烯基或炔基团; 或一个可选择取代的环烷基团; 或一个如-SR，-OR，卤素，芳基，芳基烷基，-O-芳基或-NR7R8的基团; n代表1或2; m代表从1到4的整数; R代表一个可选择取代的烷基团; 或一个可选择取代的环烷基团; R7和R8独立地代表氢，R，芳基或芳基烷基等基团; X代表氧或硫; M代表一个可选择取代的烷基团; 或一个可选择取代的环烷基团; 或一个芳基，芳基烷基，烯基，炔基或亚胺基团; 以及其农业上可接受的盐; 描述了包含这些化合物的除草剂组合物以及它们在作物保护中的应用。
• FLUORESCENT PROBES FOR QUANTIFICATION OF DNA DAMAGE AND REPAIR
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：US20210147932A1

  公开（公告）日：2021-05-20

  Probes, methods and kits for detecting and measuring abasic (AP) sites in a nucleic acid are provided. Aspects of the methods include determining glycosylase enzyme activity. Further provided herein are methods of quantifying AP sites in genomic DNA, and quantifying the amount of DNA damage. The subject probes include a fluorophore linked to an alpha nucleophile that reacts with the AP site of the nucleic acid to produce a highly fluorescent conjugate.

  提供用于检测和测量核酸中脱嘌呤（AP）位点的探针、方法和试剂盒。该方法的一些方面包括确定醇基化酶酶活性。此外，还提供了一种在基因组DNA中定量AP位点和DNA损伤量的方法。所述探针包括与α亲核试剂相连的荧光团，该试剂与核酸的AP位点发生反应，产生高度荧光的共轭物。
• HETEROCYCLIC COMPOUNDS, AND PREPARATION METHOD AND USE THEREOF
  申请人：Shanghai Institute Of Materia Medica Chinese Academy of Sciences

  公开号：EP3115361A1

  公开（公告）日：2017-01-11

  Provided are heterocyclic compounds represented by formula (I), stereoisomers or pharmaceutically acceptable salts of said compounds, a pharmaceutical composition of said compounds, and an application of said compounds in the preparation of a drug for the prevention and/or treatment of a central nervous system disease.

  本发明提供了由式（I）代表的杂环化合物、所述化合物的立体异构体或药学上可接受的盐、所述化合物的药物组合物，以及所述化合物在制备预防和/或治疗中枢神经系统疾病的药物中的应用。